Contents

List of abbreviations i

List of Figures… iii

List of Tables… v

1 Introduction 3

1.1 Alzheimer's Disease (AD) 5

1.2 Diagnostics for AD: labelling and imaging 5

1.3 Pathogenesis of AD 5

1.3.1 Amyloid β and AD pathogenesis 6

1.3.2 Hyperphosphorylation of τ and Microglial infiltration leading to neurodegeneration 7

1.4 Nanotechnology as a therapeutic tool for drug delivery across the BBB 9

1.5 Therapeutics in AD 10

1.5.1 Modulating neurotransmission 10

1.5.2 Cholinesterase system 10

1.5.3 N-methyl D-aspartate antagonism 13

1.5.4 Amyloid Targeted strategies 14

1.5.5 Modulating Aβ transport 15

1.5.6 Decreasing Aβ aggregation by passive immunization therapy 16

1.6 Memantine for the treatment of moderate to severe Alzheimer's 17

1.7 Self-Assembled Nanoscaffolds 17

2 Literature Review 21

2.1 Literature Review related to Memantine 21

2.2 Literature review on the development of memantine-loaded nanocarriers. 22

2.3 Literature Review: Self-assembled nanocarriers 24

2.4 Mechanism of action of self-assembled PLGA nanoscaffolds 26

2.5 Selection of Intrathecal route over oral route of administration 27

3 Drug and Excipient Profile 31

3.1 Memantine 31

3.1.1 Dosage and Administration 31

3.1.2 Mechanism of action of Memantine 31

3.1.3 Pharmacokinetics 32

3.2 PLGA 33

3.3 Pluronics F-127 34

3.4 Polyethylene Glycol (PEG) 35

3.5 Bone Marrow stem cell (BMSCs) 37

4 Aim and objective 41

4.1 Aim 41

4.2 Objectives 41

5 Materials and Methods 45

5.1 Preparation of nanoscaffolds 45

5.2 Methods for determination of response variables 45

5.2.1 Optimization of nanoscaffolds 45

5.2.2 Determination of Drug Loading (%) 46

5.3 Characterization of Optimised Memantine loaded Nanoscaffolds 46

5.3.1 Surface morphology (SEM) 46

5.3.2 Entrapment Efficiency and Drug Loading 47

5.3.3 Biodegradability study 47

5.3.4 Preparation of Pegylated Memantine loaded self-assembled PLGA Nanoscaffolds (PEG-MEM-PLGA) SANs 47

5.3.5 Characterization of (PEG-MEM-PLGA) SANs 49

5.4 *In-vitro* studies 51

5.4.1 Drug Release study and Kinetic model 51

5.4.2 Blood-brain barrier permeation assay (PAMPA-BBB) 52

5.5 *Ex-vivo* Study 53

5.5.1 Animal experiments 53

5.5.2 Enzyme Kinetic study against Acetylcholinesterase (AChE), Butyrylcholinesterase (BUChE and β-Secretase in Cortex and Hippocampus 53

5.5.3 Hemocompatibility study 54

5.6 Stem cell grafting 55

5.6.1 Neurobehavioral studies 56

5.6.2 Scopolamine induced amnesia model and treatment groups 56

5.6.3 Y-Maze Test 56

5.6.4 Morris Water Maze Test 57

5.7 Estimation of pro-inflammatory cytokines 58

5.7.1 Animal model and treatment groups 58

5.8 Pharmacokinetic and Biodistribution study 60

5.8.1 Animal Experiments 60

5.8.2 High Performance Liquid Chromatography analysis of the pharmacokinetic and Biodistribution study 61

5.9 Pharmacodynamic study 62

5.10 Biochemical parameters 63

5.11 Histological analysis 63

5.12 Statistical analysis 63

6 Results and Discussion 67

6.1 Experimental design 67

6.1.1 Statistical analysis of experiments 70

6.1.2 Effect on Porosity (%) and Drug loading 70

6.1.3 Prediction of optimized formulation 71

6.1.4 Analysis of Variance 72

6.1.5 Response Surface methodology 73

6.2 Characterization of Memantine loaded nanoscaffolds 78

6.2.1 Surface morphology (SEM) 78

6.2.2 Percentage porosity 80

6.2.3 Entrapment Efficiency and Drug Loading 80

6.2.4 Biodegradation study 81

6.2.5 Swelling index and water uptake study 81

6.3 Characterization of (PEG-MEM-PLGA) SANs 82

6.3.1 Drug and polymer incompatibility study (FTIR) and Thermal Characteristics (TGA and DSC) 82

6.3.2 Surface morphology (SEM, Particle size and Zeta potential) 84

6.3.3 Determination of porosity (%) 87

6.3.4 Entrapment Efficiency 87

6.3.5 Biodegradation and Swelling index study 87

6.3.6 Stability Studies 89

6.3.7 *In-vitro* studies 89

6.3.8 *Ex-vivo* study 93

6.3.9 Hemocompatibility study 99

6.3.10 Neurobehavioral Effects 100

6.4 Pharmacokinetic and Biodistribution study 109

6.4.1 HPLC Study 109

6.5 Histological study 121
6.5.1 Histological studies 121
6.6 Estimation of pro-inflammatory cytokines 123
6.6.1 Expression of pro-inflammatory cytokines in serum, cerebral, hepatic and renal tissues 125
6.6.2 Involvement of cytokines in AD 128
6.6.3 Therapeutic effect of Memantine and nanoscaffolds on inflammation in AD 129
6.6.4 Statistical Analysis 134
7 Summary 137
8 Conclusion 147
9 References 153
10 Appendix 183